Last Updated:
Sudeep Pharma Listing: Investors had invested heavily in Sudeep Pharma IPO and it was subscribed 93 times. This issue also did not disappoint the investors and gave a huge listing gain of 23 percent.
New Delhi. Sudeep Pharma shares have made a strong entry in the stock market. Sudeep Pharma’s shares were listed at Rs 730 on the National Stock Exchange (NSE). The share was also listed at Rs 725 on BSE. The price band of Sudeep Pharma IPO was Rs 563–593. In this way, this IPO has given 23% listing gain to the investors. This IPO of Rs 895 crore had already made headlines in terms of subscription, as it was subscribed 93.71 times.
Sudeep Pharma is a technology based manufacturing company, which manufactures special excipients and specialty ingredients for pharmaceutical, food and nutrition sectors. This entry of the company exceeded expectations. The shares were expected to be listed in the gray market at a 20% premium, but the actual listing left all these expectations behind.
Sudeep Pharma IPO was filled 93.71 times
The company’s IPO was open from 21 to 25 November. People invested heavily in this IPO and it was subscribed 93.71 times. Qualified Institutional Buyers (QIBs) bid 213.08 times. High Net-worth Investors filled the reserve portion 116.72 times while retail investors filled the reserve portion 15.65 times. Sudeep Pharma had raised Rs 268.50 crore from anchor investors by allotting 45.27 lakh shares on November 20.
Of the capital raised from Sudeep Pharma IPO, the company will use Rs 75.81 crore to install new machinery in its Facility-1 located in Nandesari (Gujarat), increase production capacity and meet future corporate needs. It is clear from this that the company is preparing to expand its business further in the coming time.
What does Sudeep Pharma do?
Sudeep Pharma manufactures pharmaceutical excipients, food-grade minerals and specialty nutrition ingredients. The company supplies goods to more than 100 countries. The company has six manufacturing plants. The company has a portfolio of more than 200 products.
Sudeep Pharma has shown consistent growth in the last three financial years. Revenue increased from Rs 465.38 crore in FY24 to Rs 511.33 crore in FY25, an increase of 10%. At the same time, net profit increased from Rs 133.15 crore to Rs 138.69 crore. For the June 2025 quarter, the company reported revenue of Rs 130.08 crore and profit of Rs 31.27 crore.
